PTO/SB/21 (01-03)

رن الایا S Under	r the Paperwork Reduction Act of 1995	. no person	U.S. Paters are required to respond to a collection	Approved for use through 04/30/2003. OMB 0651-0 ent and Trademark Office; U.S. DEPARTMENT OF COMMER ion of information unless it displays a valid OMB control num!		
TRANSMITTAL FORM (to be used for all correspondence after initial filing) Total Number of Pages in This Submission			Application Number	10/645,895		
			Filing Date	August 21, 2003		
			First Named Inventor	Hoffmann, et al.		
			Art Unit	1626		
			Examiner Name	Shameem, Golam M		
			Attorney Docket Number	20693 US3		
		ENCI	OSURES (Check all tha	at apply)		
Am Ex Infi	Fee Attached nendment/Reply After Final Affidavits/declaration(s) tension of Time Request press Abandonment Request formation Disclosure Statement ertified Copy of Priority becoment(s) esponse to Missing Parts/ complete Application Response to Missing Parts under 37 CFR 1.52 or 1.53		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addr Ferminal Disclaimer Request for Refund CD, Number of CD(s) ks	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):		
	SIGNA	TURE C	F APPLICANT, ATTORN	IEY, OR AGENT		
mail in an er	November 7, 2003 C tify that this correspondence is being travelope addressed to: Commissioner for	ansmitted to	ATE OF TRANSMISSION of the USPTO or deposited with the Urp.O. Box 1450, Alexandria, VA 2237	Inited States Postal Service with sufficient postage as first cla		
Tunad an	printed Kimberly الر Prior	~~~				
ypea or						

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors:

Hoffmann, et al.

Group: 1626

Serial No. 10/645,895, filed August 21, 2003

Examiner: Shameem, Golam M

(Ref. No. 20693 US3)

For:

NK-1 RECEPTOR ACTIVE AMINE OXIDE PRODRUGS

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110 November 7, 2003

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

None of the documents listed on Form PTO 1449 are being submitted because each document has been made of record in the parent application, Serial No. 10/337,543, filed January 7, 2003, now pending.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/645,895 Filed: August 21, 2003

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

Attorney for Applicant(s)

Kimberly J. Prior (Reg. No. 41,483) 340 Kingsland Street

Nutley, New Jersey 07110 Telephone: (973) 235-6208

Telefax: (973) 235-2363

135989

		Substitute for form 1449A/PTO		Comple	te if Kno	own			
IN	FORM.	ATION DISCLOSURE		Application Number 10/645,895					
		ENT BY APPLICANT		Filing Date		August 21, 2003			
			I	First Name Inventor		offmann, et al.			
1 0 2003 🗟	(Use se	veral sheets if necessary)		Group Art Unit 1626					
C;	<i>}</i>			Examiner Name					
Sheet?	1	of 1		Attorney Docket Number	20693	US3			
		U.S. Patent Document		NT DOCUMENTS					
Examiner Initials'	Cite No. ¹	Number (if known)		Name of Patentee or Applicant of Cited Document Dorn et al.		Date of Publication of Cited document MM-DD-YYYY 11/25/1997			
	A1 5,691,336								
	A2	5,972,938		Rupniak et al.		10/26/1999			
	A3 6,297,375			Bos et al.	10/02/2001				
	-		GN PA	TENT DOCUMENTS					
Examiner Initials'	Cite	Foreign Patent Document Office ³ Number ⁴ Kind Cod		Name of Patentee or		cited Document	T ⁶		
	No.¹		(nown)	Applicant of Cited Docum Merck & Co.		MM-DD-YYYY /22/1995			
	B2	WO 95/18124		 		07/06/1995			
	IDZ.	W O 75/10124		Dohme	07				
	B3	WO 95/23798		Merck & Co.		09/08/1995			
	B4 EP 103 545			F.Hoffmann-La Roche 05		/30/2001			
	B5	EP 035 115		F.Hoffmann-La Roc	/13/2000				
		NON PATE	NT LIT	ERATURE DOCUMENT	'S				
Examiner Initials'									
	C1	Hans Bundgaard, Drugs of the Future, Vol. 16(5), pp. 443-458 (1991)							
	C2	Barker, Reviews in the Neurosciences, Vol. 7, No. 3, pp. 187-214 (1996)							
	C3		nysiol. Pharmacol., Vol	1. 75, p	p. 612-621				
-	C4	Mark S. Kramer et al., Science, Vol. 281, pp. 1640-1645							
	C5	Maggi et al., J. Auton. Pharmacol, Vol. 13, pp. 23-93 (1993)							
	C6								
	pp. 190-195 (1999)								
	C7								
_	C8 Doi etal., European Journal of Pharmacology, Vol. 383(3), pp. 297-303 (1999)								
	C9 Yoshinori Ikeura et al., Chem. Pharm. Bull., Vol. 45(10), pp. 1642-								
	1652 (1997)								
Examiner	Date Considered:								
Signature	Initial if safes	ence considered, whether or not citation is in	conformance	with MDED 600. Draw line through sitetion	if not in confe	emance and not considered. Inc	lude conv		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this

form with next communication to applicant.

Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation or abstract is attached.